UBS Reiterates Buy Rating on Kura Oncology (KURA)

October 5, 2026 5:37 AM

UBS analyst David Dai reiterated a Buy rating and $15.00 price target on Kura Oncology (NASDAQ: KURA).The analyst comments "KURA's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found